PAMU
TEVA icon

Pictet Asset Management (UK)’s Teva Pharmaceuticals TEVA Stock Holding History

Pictet Asset Management (UK)’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$3.35M Buy
336,450
+28,400
+9% +$301K ﹤0.01% 927
2021
Q1 		$3.51M Sell
308,050
-13,247
-4% -$152K ﹤0.01% 908
2020
Q4 		$3.06M Buy
321,297
+8,260
+3% +$79.1K ﹤0.01% 913
2020
Q3 		$2.84M Sell
313,037
-19,670
-6% -$208K ﹤0.01% 845
2020
Q2 		$4M Buy
332,707
+14,478
+5% +$164K 0.01% 741
2020
Q1 		$2.93M Buy
318,229
+13,010
+4% +$133K 0.01% 774
2019
Q4 		$3.02M Buy
305,219
+9,739
+3% +$86.9K 0.01% 863
2019
Q3 		$2.03M Sell
295,480
-1,860
-0.6% -$14.3K ﹤0.01% 862
2019
Q2 		$2.73M Buy
297,340
+36,587
+14% +$441K 0.01% 817
2019
Q1 		$4.06M Sell
260,753
-10,312
-4% -$182K 0.01% 744
2018
Q4 		$4.25K Buy
271,065
+4,400
+2% +$90.2K 0.01% 696
2018
Q3 		$5.85M Sell
266,665
-1,100
-0.4% -$25.5K 0.01% 693
2018
Q2 		$6.51M Sell
267,765
-51,964
-16% -$1.06M 0.02% 607
2018
Q1 		$5.46M Sell
319,729
-6,610
-2% -$129K 0.01% 647
2017
Q4 		$6.18M Sell
326,339
-29,012
-8% -$436K 0.02% 614
2017
Q3 		$6.25M Sell
355,351
-2,671,134
-88% -$60.1M 0.02% 587
2017
Q2 		$84.3M Buy
3,026,485
+12,397
+0.4% +$384K 0.26% 118
2017
Q1 		$96.7M Sell
3,014,088
-30,503
-1% -$1.04M 0.32% 91
2016
Q4 		$110M Buy
3,044,591
+1,302,198
+75% +$52M 0.41% 66
2016
Q3 		$80.2M Buy
1,742,393
+1,397,920
+406% +$72.9M 0.3% 92
2016
Q2 		$17.9M Sell
344,473
-39,104
-10% -$2.08M 0.07% 320
2016
Q1 		$21.3M Buy
383,577
+89,933
+31% +$5.28M 0.09% 247
2015
Q4 		$19.3M Buy
293,644
+71,520
+32% +$4.42M 0.08% 288
2015
Q3 		$12.5M Buy
222,124
+28,992
+15% +$1.88M 0.06% 356
2015
Q2 		$13.3M Sell
193,132
-609,420
-76% -$37.6M 0.05% 368
2015
Q1 		$48.5M Buy
802,552
+759,150
+1,749% +$44.1M 0.2% 132
2014
Q4 		$2.5M Buy
43,402
+7,300
+20% +$407K 0.01% 715
2014
Q3 		$1.94M Sell
36,102
-2,500
-6% -$132K 0.01% 738
2014
Q2 		$2.02M Buy
38,602
+6,100
+19% +$312K 0.01% 734
2014
Q1 		$1.72M Buy
32,502
+13,300
+69% +$615K 0.01% 752
2013
Q4 		$770K Sell
19,202
-2,400
-11% -$94.5K ﹤0.01% 794
2013
Q3 		$816K Buy
21,602
+4,300
+25% +$168K ﹤0.01% 786
2013
Q2 		$678K Buy
+17,302
New +$674K ﹤0.01% 791

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

Pictet Asset Management (UK)'s TEVA Position: Q2 2021 in Review

Pictet Asset Management (UK) increased its Teva Pharmaceuticals (TEVA) stake by 9.2% in Q2 2021, buying an estimated $301K and bringing the position to 336,450 shares worth $3.35M. The position accounts for ﹤0.01% of the portfolio, ranked #927.

Pictet Asset Management (UK) first reported a position in TEVA in Q2 2013 and has held it in 33 quarters since. The position peaked at $110M in Q4 2016. 440 funds tracked by Wall St. Rank hold TEVA as of Q2 2021.

  • Pictet Asset Management (UK) held 336,450 shares of Teva Pharmaceuticals worth $3.35M as of Q2 2021.
  • Pictet Asset Management (UK) bought 28,400 Teva Pharmaceuticals shares in Q2 2021, an estimated $301K.
  • Teva Pharmaceuticals made up ﹤0.01% of Pictet Asset Management (UK)'s portfolio in Q2 2021, its #927 holding.
  • Pictet Asset Management (UK) first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 33 quarters since.
  • Pictet Asset Management (UK)'s Teva Pharmaceuticals position peaked at $110M in Q4 2016.
  • 440 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2021.

Based on Pictet Asset Management (UK)'s 13F filing for Q2 2021, filed 16 Aug 2021.